INTRODUCTION
Endoscopic biliary drainage by stenting has become a standard management for obstructive jaundice caused by malignancy. [1] [2] [3] [4] Endoscopic stent insertion for an obstructed biliary tract was first performed by Soehendra and Reynders-Frederix in 1980 3 and since then, has become a widely established method to relieve cholangitis and pain and reduce mortality and morbidity from malignant biliary obstruction. 5 However, (PS) and metal stent (MS). Although many studies have shown a longer survival and less need for re-intervention with MS compared to PS, PS is usually first tried in biliary tract cancer. 6 PSs are easier to remove and cheaper compared to MS. Moreover, it is a difficult decision as to when to insert MS because the biliary stricture may not be confirmed or staging work-up is not finished. PSs can be easily removed by forceps and a biopsy or brush cytology can be retried to obtain tissue samples from lesions.
There are various diameters of plastic stents, ranging from 5-French (FR) to 12-Fr. 7 A few studies report that small stents provide better survival, while most studies report that larger stents are better. 8, 9 The outer diameter of plastic stents is limit- 3. Outcomes measure and follow-up schedule the chi-square test was used to compare categorical measures.
Changes in laboratory levels before and after stent insertion were compared within the same group using a paired t -test.
To assess differences in laboratory levels between the two groups at baseline and after stent insertion, we performed a linear mixed model for repeated measurements. Two effects were included: one within-group time effect (before and after stent insertion) and one between-group stent diameter effect.
Cox regression analysis was used to identify the factors affecting stent survival. A significant difference was noted when the p value was < 0.05.
RESULTS

Patient characteristics
A total of 215 patients with biliary tract cancer underwent ERCP for decompression of the bile duct (Table 1) 
Clinical outcomes and stent survival
The technical success rates of stent insertion were 100% in both groups ( Table 2 ). The number of patients who need to change stents during follow up was not different between the two groups. The median stent survival between the 7-Fr group and 10-Fr group was not statistically different (3.3 months vs.
5.9 months, p = 0.543, Fig. 1 ). The cumulative stent survival rates for 7-Fr PS at 6 and 12 months were 48% and 42%, respectively. The cumulative stent survival rate for 10-Fr PS at 6 and 12 months were 51% and 42%, respectively. The levels of AST, ALT, and total bilirubin decreased significantly after stent insertion in both groups. According to linear mixed-model analysis, the changes in AST, ALT, and total bilirubin between groups were not significant ( Table 3) . We tried to identify factors affecting stent survival by using Cox regression analysis (Table 4 ). The hazard ratio of 7-Fr PS was 1.11 (95% confidence interval [CI], 0.71-1.73) but it was not significant (p = 0.649). 10 Endoscopic stenting has a lower early mortality and fewer complications than surgical management, but these patients require follow-up ERCP to exchange the stent when necessary for obstruction or migration. 1, 11, 12 Stent obstruction is a clinically significant problem and many attempts have been made to improve stent survival.
Most causes of stent failure and obstruction are tumor overgrowth, ingrowth, and bile sludge. Since deposition of sludge in biliary stents is not preventable, effective attempts to prolong stent survival currently require the use of large-diameter stents. In the opinion of many expert endoscopists, with the availability of ERCP for larger-sized stents, there is a tendency towards placing stents of 10-Fr or larger because they believe that the larger-sized stents are more effective for jaundice and have a lower incidence of obstruction. Several reports have attested 10-Fr or larger stents are more effective for biliary drainage. 9,13,14 Rey et al. 15 reported that increasing the stent internal diameter by 0.2 mm increased the bile flow by 300%.
Siegel et al. 14 showed that the duration of survival of 12-Fr PS was longer than that of 10-Fr PS (190 vs 150 days) and recommended routine use of larger stents. On the other hand, some retrospective studies failed to show that larger stents have any significant effect in palliative management or duration of stent survival. 8, 16, 17 The question whether a larger diameter is significantly better for a PS has clinical importance because the PS has been often used for the palliation of patients with malignant biliary obstruction. 18, 19 In our study, we compared the stent survival However, a 13.9% complication rate for 7-Fr PS occurred as compared with a 16.7% complication rate for 10-Fr PS. 20 The levels of AST, ALT, and total bilirubin were effectively decreased after stent insertion regardless of stent diameter.
Moreover, the differences were not statistically significant on linear mixed-models. In addition, the stent diameter was not related to stent survival by Cox regression analysis. Matsuda et al. 16 reported that factors such as diameter and length of the PS were not significantly related to duration of survival. Sasahira et al. 21 also failed to show PS with a larger diameter prolonged stent survival.
In our study, the success rate of stent insertion was 100%
for both 7-Fr and 10-Fr stents. The 10-Fr stents were more difficult to insert and handle because of the stricture of biliary duct although the time to stent insertion was not measured.
Smaller-caliber stents such as 7-Fr PS have an advantage when entering tight strictures that are difficult to traverse, 7 There are some limitations to this study. First, the study is retrospective and not randomized. Although the success rate was 100% in both groups in this study, the endoscopists might have selected 7-Fr PS rather than 10-Fr PS in difficult cases because a smaller diameter PS is more flexible and easier to insert into an obstructed bile duct than a larger diameter PS.
Therefore, bias could have occurred. Second, the tumor sites were heterogeneous and the length of the stent differed according to the tumor site. Third, the procedure time was not evaluated to compare the feasibility of stent insertion. However, quite a large number of cases were analyzed and multivariate analysis was performed to consider confounding factors.
In conclusion, our study demonstrated that 7-Fr stents have similar stent migration or stent obstruction rate to 10- 
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